Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 13 sources cited
Key Takeaways
- Tirzepatide is a once-weekly injection that activates two gut hormone receptors at once: GIP and GLP-1. It is the first dual incretin agonist approved for human use.
- It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.
- In the SURMOUNT-1 trial, adults without diabetes lost an average of 22.5% of body weight at 72 weeks on tirzepatide 15 mg weekly, versus 2.4% on placebo (Jastreboff et al., NEJM 2022).
- Tirzepatide produces more weight loss on average than semaglutide in head-to-head trials (Aronne et al., NEJM 2025).
- Common side effects are gastrointestinal and dose-dependent. Most are mild to moderate and concentrated during titration.
Direct answer (40-60 words)
Tirzepatide is a once-weekly injectable medication that activates both GIP and GLP-1 receptors, mimicking two gut hormones at once. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Adults in the SURMOUNT-1 trial lost an average of 22.5% of body weight at 72 weeks.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- What tirzepatide is, in plain language
- How tirzepatide works: two receptors, one molecule
- Mounjaro vs Zepbound: same drug, different labels
- Who tirzepatide is approved for
- The clinical evidence: SURPASS, SURMOUNT, SUMMIT
- Dosing and titration
- Side effects and safety
- Tirzepatide compared with semaglutide
- Compounded tirzepatide
- What to expect in the first 6 months
- FAQ
- Sources
- Footer disclaimers
What tirzepatide is, in plain language
Tirzepatide is a synthetic peptide that copies parts of two natural gut hormones at the same time. The hormones are GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are released after meals and both help regulate blood sugar, appetite, and digestion.
Older diabetes and obesity drugs in this family targeted only GLP-1. Tirzepatide is the first medication to activate both receptors with a single molecule. The technical term is "dual GIP and GLP-1 receptor agonist," or "twincretin."
It was developed by Eli Lilly and approved by the FDA as Mounjaro in May 2022 for type 2 diabetes. The same molecule was approved as Zepbound for chronic weight management in November 2023 and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.
The drug is delivered once a week as a subcutaneous injection. It comes in single-dose pens or vials at six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
How tirzepatide works: two receptors, one molecule
The novelty of tirzepatide is hitting GIP and GLP-1 receptors simultaneously. The two receptors do overlapping but distinct things.
GLP-1 effects (the part that overlaps with semaglutide):
- Triggers glucose-dependent insulin release from the pancreas
- Suppresses inappropriate glucagon secretion
- Slows gastric emptying
- Activates appetite-suppressing neurons in the hypothalamus and brainstem
GIP effects (the part tirzepatide adds):
- Enhances insulin secretion in response to food, especially fats
- Affects fat metabolism in adipose tissue, including how fat is stored and broken down
- May reduce nausea signaling, which helps explain why patients often tolerate tirzepatide despite stronger weight loss
- Modulates energy expenditure in animal studies (less clear in humans)
The combined effect is stronger glycemic control and stronger weight loss than GLP-1 alone, with side-effect rates that are similar (not double) those of GLP-1 monotherapy. The current best explanation is that GIP activation partially counterbalances GLP-1-driven nausea while adding to insulin and energy effects (Samms et al., Trends Endocrinol Metab 2020).
In practical terms: tirzepatide does what semaglutide does, then adds an extra layer.
Mounjaro vs Zepbound: same drug, different labels
The molecule is identical. The brand, packaging, indication, and dosing schedule differ.
| Brand | Indication | Pen colors | Dose strengths |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Mixed (varies by year) | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Zepbound | Chronic weight management; obstructive sleep apnea with obesity | Mixed (varies by year) | 2.5, 5, 7.5, 10, 12.5, 15 mg; also single-dose vials |
Single-dose vials of Zepbound were introduced in 2024 at lower out-of-pocket prices for cash-pay patients without insurance coverage.
Insurance coverage and savings programs differ between the two brands. Mounjaro is covered by most commercial insurance for type 2 diabetes. Zepbound coverage for weight management has improved but remains inconsistent across plans.
Who tirzepatide is approved for
The FDA labels are specific.
Mounjaro (type 2 diabetes):
- Adults with type 2 diabetes mellitus, as an adjunct to diet and exercise to improve glycemic control.
Zepbound (chronic weight management):
- Adults with a body mass index (BMI) of 30 or higher, or
- Adults with a BMI of 27 or higher plus at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.
Zepbound (obstructive sleep apnea):
- Adults with moderate-to-severe OSA and obesity (BMI of 30 or higher), as an adjunct to a reduced-calorie diet and increased physical activity.
Tirzepatide is not approved for type 1 diabetes, pregnancy, breastfeeding, children under 18, or in patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. It is used cautiously in patients with severe gastroparesis or active pancreatitis.
The clinical evidence: SURPASS, SURMOUNT, SUMMIT
Three trial families anchor what we know about tirzepatide.
SURPASS (diabetes program). Five trials enrolling about 6,200 adults with type 2 diabetes. Across SURPASS 1 through 5, tirzepatide reduced HbA1c by 1.9 to 2.6 percentage points and produced 7 to 13 kg of weight loss as a secondary outcome (Frias et al., NEJM 2021; Ludvik et al., Lancet 2021). SURPASS-2 directly compared tirzepatide to semaglutide 1 mg in type 2 diabetes and found tirzepatide superior on both glycemic and weight endpoints.
SURMOUNT (obesity program). SURMOUNT-1 enrolled 2,539 adults with obesity but without diabetes, randomized to placebo or tirzepatide 5 mg, 10 mg, or 15 mg weekly for 72 weeks. Mean weight loss:
| Group | Mean weight loss |
|---|---|
| Tirzepatide 5 mg | 15.0% |
| Tirzepatide 10 mg | 19.5% |
| Tirzepatide 15 mg | 20.9% |
| Placebo | 3.1% |
(Jastreboff et al., NEJM 2022). Around 57% of the 15 mg group lost 20% or more of their body weight, and 36% lost 25% or more.
SURMOUNT-2 (in adults with type 2 diabetes) showed 12 to 15% weight loss, lower than in non-diabetic patients but still substantially better than placebo (Garvey et al., Lancet 2023). SURMOUNT-3 paired tirzepatide with intensive lifestyle intervention and found that patients who first lost weight on a low-calorie diet then continued on tirzepatide lost an additional 18.4% versus regaining on placebo. SURMOUNT-4 looked at withdrawal: patients who stopped tirzepatide regained roughly 14% of body weight within a year (Aronne et al., JAMA 2024).
SURMOUNT-5 was the head-to-head against semaglutide 2.4 mg in non-diabetic adults with obesity. At 72 weeks, mean weight loss was 20.2% with tirzepatide and 13.7% with semaglutide (Aronne et al., NEJM 2025).
SUMMIT (obstructive sleep apnea). Two trials enrolling adults with moderate-to-severe OSA and obesity. Tirzepatide reduced the apnea-hypopnea index (a measure of breathing disturbances per hour of sleep) by about 25 to 30 events per hour at 52 weeks, alongside meaningful weight loss (Malhotra et al., NEJM 2024). This data drove the December 2024 FDA approval for OSA.
A separate cardiovascular outcome trial, SURPASS-CVOT, is ongoing. The current cardiovascular signal for tirzepatide is favorable but not yet at the level of evidence semaglutide has from SELECT.
Dosing and titration
Tirzepatide is started at 2.5 mg weekly for the first month and increased every 4 weeks as tolerated.
Standard titration schedule:
| Weeks | Dose |
|---|---|
| 1-4 | 2.5 mg weekly |
| 5-8 | 5.0 mg weekly |
| 9-12 | 7.5 mg weekly |
| 13-16 | 10.0 mg weekly |
| 17-20 | 12.5 mg weekly |
| 21+ | 15.0 mg weekly (maximum) |
The 2.5 mg starting dose is not therapeutic. It exists for tolerability. Most patients begin to feel appetite suppression at 5 mg or 7.5 mg. Glycemic and weight-loss benefits are dose-dependent up to 15 mg.
Many patients reach maintenance at 10 mg or 12.5 mg, especially when weight-loss goals have been met or side effects make further escalation uncomfortable. There is no medical requirement to reach 15 mg if the lower dose produces adequate response.
If side effects are severe at any step, the schedule can pause for an additional 4 weeks at the current dose or back down a level. Pushing the titration aggressively is the strongest predictor of intolerable nausea and vomiting.
Side effects and safety
The most common side effects are gastrointestinal and dose-dependent. From SURMOUNT-1 data (15 mg group):
| Side effect | Tirzepatide 15 mg | Placebo |
|---|---|---|
| Nausea | 31.0% | 9.5% |
| Diarrhea | 23.0% | 7.3% |
| Constipation | 11.7% | 6.1% |
| Vomiting | 12.2% | 1.7% |
| Decreased appetite | 11.1% | 1.4% |
| Acid reflux | 9.4% | 4.1% |
Most GI side effects are mild to moderate and resolve as the dose stabilizes. About 4.3% of patients in SURMOUNT-1 discontinued for adverse events, comparable to placebo.
Less common but more serious risks:
- Pancreatitis. Rare. Severe upper abdominal pain radiating to the back warrants immediate evaluation.
- Gallbladder disease. Increased risk during rapid weight loss. Right-upper-quadrant pain after fatty meals deserves imaging.
- Hypoglycemia. Rare with tirzepatide alone. More common when combined with insulin or sulfonylureas.
- Acute kidney injury. Usually secondary to dehydration from severe vomiting or diarrhea.
- Hypersensitivity reactions. Rare but reported.
- Thyroid C-cell tumors. Boxed warning based on rodent studies; no confirmed human signal. Contraindicated in patients with personal or family history of medullary thyroid carcinoma.
- Severe gastroparesis. Caution in patients with pre-existing gastroparesis. Tirzepatide can worsen the condition.
For protocols on managing common side effects, see /articles/side-effects/glp1-nausea-protocol/ and /articles/side-effects/glp1-constipation-protocol/.
Tirzepatide compared with semaglutide
Both are weekly injections used for diabetes and obesity. The differences:
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GLP-1 only |
| FDA approval | Mounjaro 2022; Zepbound 2023 | Ozempic 2017; Wegovy 2021 |
| Average weight loss (head-to-head) | 20.2% at 72 weeks | 13.7% at 72 weeks |
| Cardiovascular outcomes data | SURPASS-CVOT pending | SELECT confirmed 20% MACE reduction |
| Maximum dose | 15 mg weekly | 2.4 mg weekly (Wegovy) |
| Sleep apnea indication | Yes (Zepbound, 2024) | No |
Tirzepatide produces more weight loss on average and more glycemic improvement in head-to-head data (Aronne et al., NEJM 2025; Frias et al., NEJM 2021). Semaglutide has the longer track record and the only confirmed cardiovascular outcomes data in the obesity population from SELECT (Lincoff et al., NEJM 2023).
For a deeper comparison see /articles/comparison/semaglutide-vs-tirzepatide/.
Compounded tirzepatide
Compounded tirzepatide is prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not an FDA-approved product.
During the FDA-declared shortage of brand-name tirzepatide, large-scale compounding was permitted under specific exemptions. The shortage was resolved in October 2024, after which the legal pathway for compounding tirzepatide narrowed significantly. Compounding now generally requires a clinical reason that an FDA-approved product cannot meet, such as an allergy to a non-active ingredient or a dose strength the brand does not produce.
Compounded versions are not interchangeable with brand-name tirzepatide. Active ingredient concentration, excipients, and stability data vary by compounding pharmacy. Reputable platforms work only with 503A or 503B pharmacies and require a state-licensed provider's prescription.
For the long version of this topic, see /articles/compounded/why-compounded-tirzepatide-red/.
What to expect in the first 6 months
Rough timeline based on aggregated trial data and clinical experience.
Weeks 1-4 (2.5 mg). Mild nausea, possibly mild appetite suppression. Weight loss minimal. The 2.5 mg dose is mostly there to acclimate the gut.
Weeks 5-8 (5 mg). Stronger appetite suppression. Average weight loss in SURMOUNT-1 by week 8 on the 5 mg arm was about 4 to 5% of body weight. Many patients describe "food noise" reducing here.
Weeks 9-16 (7.5 to 10 mg). Substantial appetite suppression. Average weight loss approaches 10% by week 16. Energy levels often improve as caloric deficit normalizes.
Weeks 17-24 (12.5 to 15 mg). Maximum or near-maximum dose. Average weight loss in SURMOUNT-1 by week 24 on the 15 mg arm was around 13 to 15% of body weight, on the way to the 22.5% endpoint at 72 weeks.
About 9 to 14% of patients are non-responders (less than 5% weight loss at 6 months) depending on dose. The 6-month checkpoint is the standard time to evaluate continuation, dose change, or alternative therapy.
FAQ
What is tirzepatide used for? Tirzepatide is FDA-approved for type 2 diabetes (as Mounjaro), chronic weight management (as Zepbound), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound). It is also being studied for cardiovascular outcomes, kidney disease, and metabolic-associated steatohepatitis.
Is tirzepatide the same as Mounjaro? Mounjaro is a brand name for tirzepatide. Zepbound is also tirzepatide. The molecule is identical. The difference is the FDA-approved label: Mounjaro is for type 2 diabetes; Zepbound is for weight management and OSA.
How does tirzepatide cause weight loss? Tirzepatide activates two gut hormone receptors (GIP and GLP-1). It reduces hunger by acting on appetite centers in the brain, slows gastric emptying so you feel full longer, and lowers spontaneous calorie intake. Average weight loss is around 22.5% at 72 weeks on the 15 mg dose.
How long does tirzepatide take to work? Appetite changes can begin within the first 1 to 2 weeks. Meaningful weight loss typically starts around weeks 4 to 8 as the dose increases. Average weight loss at 12 weeks in SURMOUNT-1 was about 7 to 8% of body weight, building toward the maximum effect around 60 to 72 weeks.
Is tirzepatide stronger than semaglutide? On average, yes, for weight loss and glycemic control. In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. Individual response varies, and some patients respond better to semaglutide.
Do you regain weight after stopping tirzepatide? Most patients regain a substantial portion of lost weight. In SURMOUNT-4, patients who stopped tirzepatide regained about 14% of body weight within a year. Weight maintenance after stopping is possible but uncommon without continued lifestyle and behavioral support.
Is tirzepatide safe? For most patients, yes. The most common side effects are gastrointestinal and usually mild to moderate. Serious risks are uncommon. It is contraindicated in patients with a history of medullary thyroid carcinoma or MEN-2 syndrome and used cautiously in severe gastroparesis or active pancreatitis.
Can men take tirzepatide? Yes. Tirzepatide is approved for both men and women. The mechanism, efficacy, and side-effect profile are similar across sexes, though men in trials often lose slightly more absolute weight while women lose a similar percentage of body weight.
Is tirzepatide a steroid? No. Tirzepatide is a peptide that mimics the natural hormones GIP and GLP-1. It has no relationship to steroid hormones and does not cause the side effects associated with steroids.
Can tirzepatide cause hair loss? Some patients report increased hair shedding during rapid weight loss, regardless of the cause. This is called telogen effluvium and is usually temporary. It is not a direct effect of tirzepatide on hair follicles. Adequate protein intake (0.8 to 1.0 g per pound of goal body weight) and patience usually resolve it within 6 to 12 months.
Is tirzepatide covered by insurance? Coverage varies. Mounjaro is widely covered for type 2 diabetes. Zepbound coverage for weight loss is improving but inconsistent and often requires prior authorization. Medicare currently does not cover Zepbound for weight loss alone.
How is tirzepatide given? As a subcutaneous injection once weekly into the abdomen, thigh, or upper arm. Single-dose pens and vials are available. The dose is the same regardless of injection site, and the injection should be rotated to a different spot each week to reduce skin irritation.
Sources
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331:38-48.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
- Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin (SURPASS-3). Lancet. 2021;398:583-598.
- Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SUMMIT). N Engl J Med. 2024.
- Samms RJ, et al. How may GIP enhance the tolerability and efficacy of GLP-1 receptor agonists? Trends Endocrinol Metab. 2020;31:410-421.
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. 2024 update.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. 2024 update.
- American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription medications to treat overweight and obesity. 2024.
- American College of Cardiology. Expert consensus on cardiovascular risk reduction with GLP-1 receptor agonists. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →